BPC-157

Tissue Repair & Recovery

Also known as: Body Protection Compound, PL 14736

BPC-157 — a peptide studied for tissue repair, musculoskeletal recovery, and gut and nervous system protection.

Evidence snapshot

A high-level read on what the published literature does and does not yet show.

Primary research themes
Gastrointestinal protection, Tendon and ligament repair, Wound healing, Anti-inflammatory effects
Human data
Limited
Preclinical data
Extensive
Studied areas
Rodent gut injury models, Tendon healing, Vascular angiogenesis, NSAID-induced damage
Key uncertainty
Nearly all evidence is preclinical; human pharmacokinetics and long-term safety have not been characterized in controlled trials.
Regulatory note
Not FDA-approved for the uses discussed

Storage stability

Lyophilized, room temp
Lyophilized, refrigerated
Lyophilized, frozen
Reconstituted, refrigerated
Reconstituted, room temp

No measured storage-stability data (lyophilized or reconstituted vial shelf-life) for BPC-157 located across any source tier as of 2026-05-22. T1 peer-reviewed literature (PubMed): "BPC-157 stability", "BPC 157 degradation", "BPC-157 lyophilized" (0 results), "BPC-157 HPLC", "BPC-157 aqueous solution stability" (0 results), "BPC-157 half-life pharmacokinetics", "PL 14736 stability" — 34 PMIDs surfaced, none report vial storage. T2 FDA-approved label/insert: none — BPC-157 is not FDA-approved (FDA 2023 Review Memorandum declined 503B Bulks listing), so no drug label or storage section exists. T3 manufacturer COAs / vendor lab data: no testing documents tracked for any of the 9 BPC-157 vendor offers; published vendor pages recite storage rules of thumb without a measured study, methodology, or timepoint COA data (excluded as marketing per spec §2). T4 USP/ICH standards: define stability-testing frameworks only, not a BPC-157 class-specific day-count. Related findings describing biological or matrix stability, not vial storage, and not used to fill cells: in vivo elimination half-life under 30 min in rats and dogs (PMID 36588717); analyte stable in urine at least 4 days for doping detection (PMID 28035768); no degradation in human gastric juice beyond 24 h (PMID 35125818).

On this page

Mechanism

BPC-157
VEGFR2 → Akt → eNOS → NO → angiogenesis pathway

Depicts one of several proposed mechanisms. See the references below for the underlying literature. Not a complete account of how this peptide acts.

BPC-157 VEGFR2–Akt–eNOS–NO angiogenesis pathwayA six-step cascade. BPC-157 binds and upregulates VEGFR2. VEGFR2 activates PI3K signaling to Akt. Akt phosphorylates eNOS. eNOS produces nitric oxide. Nitric oxide drives angiogenesis — the formation of new capillaries.BPC-157peptideVEGFR2receptorAktkinaseeNOSenzymeNOnitric oxideAngiogenesiscapillary formationbinds & upregulates[1]activates PI3K signaling[1][2]phosphorylates[2]produces[2][3]drives[3][4]
  1. [1] Hsieh M-J, Liu H-T, Wang C-N, et al. Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation and up-regulation. J Mol Med (Berl) 2017. PubMed →
  2. [2] Hsieh M-J, Lee C-H, Chueh H-Y, et al. Modulatory effects of BPC 157 on vasomotor tone and the activation of Src-Caveolin-1-endothelial nitric oxide synthase pathway. Scientific Reports 2020. PubMed →
  3. [3] Sikiric P, Seiwerth S, Skrtic A, et al. BPC 157 Therapy: Targeting Angiogenesis and Nitric Oxide's Cytotoxic and Damaging Actions, but Maintaining, Promoting, or Recovering Their Essential Protective Functions. Pharmaceuticals 2025. PubMed →
  4. [4] Józwiak M, Bauer M, Kamysz W, Kleczkowska P Multifunctionality and Possible Medical Application of the BPC 157 Peptide — Literature and Patent Review. Pharmaceuticals 2025. PubMed →

BPC-157, short for Body Protection Compound, is a 15-amino-acid peptide originally isolated from human gastric juice — part of the body's own protective system that keeps the stomach lining intact in a hostile chemical environment. Researchers became interested in it because the molecules that protect the gut tend to have repair-promoting effects elsewhere in the body too.

Three decades of laboratory work have built BPC-157 a reputation as a broad-spectrum recovery peptide. It's been studied across tendons, ligaments, muscle, bone, the gut lining, and even nervous tissue, and the consistent finding is that it appears to accelerate healing wherever it's tested. The peptide is short-lived in circulation — under 30 minutes — but its effects on tissue persist, suggesting it works by triggering longer-lasting cellular repair processes rather than acting directly.

What makes it stand out among peptides is the breadth of effects from a single small molecule. Most compounds with healing potential are narrowly targeted; BPC-157 seems to work through general mechanisms that show up wherever damaged tissue needs to rebuild — primarily by promoting the formation of new blood vessels and modulating inflammation in the recovery zone.

BPC-157 and Tendon, Ligament, and Muscle Recovery

Connective tissue is where BPC-157 has been studied most thoroughly. A 2025 systematic review covering 36 studies of musculoskeletal applications reported consistent improvements in functional, structural, and biomechanical outcomes after tendon ruptures, ligament tears, muscle injuries, and fractures (1). A separate 2025 narrative review reached similar conclusions, describing robust regenerative and cytoprotective effects across the connective-tissue literature (2).

The mechanism behind these effects appears to center on blood supply. Tendons and ligaments are notoriously slow to heal because they're poorly vascularized — there simply aren't many blood vessels reaching the tissue to deliver the cells and signals needed for repair. BPC-157 may help by promoting angiogenesis, the formation of new blood vessels, through a signaling pathway involving VEGFR2 (a receptor that triggers blood vessel growth) and the Akt-eNOS axis, which produces nitric oxide to relax and expand vessels (1, 2). It also engages ERK1/2 signaling, a pathway involved in cell proliferation and tissue rebuilding, and appears to upregulate growth hormone receptor expression — effectively making repair cells more responsive to the body's own healing signals (1).

BPC-157 and Joint Pain

A small retrospective study followed 16 patients who received intra-articular injections of BPC-157 — directly into the knee joint — for various types of knee pain, including osteoarthritis, meniscus issues, and ligament problems (3). Among the 12 patients who received BPC-157 alone, 11 (about 92%) reported significant improvement in pain. When the overall group was considered, including those who received BPC-157 combined with thymosin-beta-4, roughly 88% reported relief.

This was a small, uncontrolled chart review based on phone follow-up rather than a rigorous trial, so the findings are preliminary. But it's one of the few pieces of human data on BPC-157 to date, and the directional signal — that joint injection of the peptide may help with multiple types of knee pain — aligns with the broader preclinical picture of a compound that promotes repair in poorly vascularized tissue (3). Larger controlled studies would be needed to confirm the effect and clarify which knee conditions respond best.

BPC-157 and the Nervous System

Beyond connective tissue, BPC-157 has been studied for effects on the brain and spinal cord. A dedicated review summarized work showing the peptide may counteract neuronal damage following stroke-like events, support recovery of memory, locomotion, and coordination after brain injury, and accelerate functional recovery after spinal cord compression — including return of movement after compression injuries (4).

Mechanistically, the same themes recur: modulation of the nitric oxide system, support for blood vessel function in damaged tissue, and reduction of inflammation around injured nerves (4). The peptide also appears to interact with dopamine signaling pathways, which is why it's been examined in models of schizophrenia-like symptoms and movement disorders. The breadth of nervous-system findings has made BPC-157 a recurring subject of interest for neurological repair, though as with the rest of the literature, this work is largely preclinical.

BPC-157 and Gut Healing

Because BPC-157 was originally isolated from gastric juice, its effects on the digestive tract are arguably the most foundational part of its research story. A 2025 review covering its broader medical potential summarized findings across models of inflammatory bowel disease and various forms of gut injury, where the peptide appears to protect and restore the intestinal lining (5).

The same protective mechanisms that show up elsewhere — promoting new blood vessel formation, dampening inflammation, supporting the integrity of the tissue barrier — seem to operate in the gut as well. This is part of why BPC-157 is sometimes described as a "gut-brain axis" compound: the peptide that originated in the stomach appears to exert protective effects throughout the body, and the gut itself remains one of the tissues where its effects have been most consistently observed (5).

Risks and what to know

Reported side effects in the published research are minimal — across the preclinical literature and the small human studies available, no significant adverse effects have been documented (1, 2, 3, 5). Long-term safety in humans hasn't been formally characterized because large-scale clinical trials haven't been completed. Anecdotally, some users report mild local effects with injection (tingling, brief redness at the site) and occasional fatigue in the first few days of use, which typically resolves.

The body of BPC-157 evidence comes primarily from preclinical and laboratory work, with limited human clinical data so far.

BPC-157 was temporarily on the World Anti-Doping Agency's prohibited list in 2022 and remains banned in some professional sports — relevant context for competitive athletes regardless of its current status (5).

Vendor preview

Lowest in-stock listings, sorted by price per milligram.

Top in-stock vendor listings for BPC-157 by price per milligram.
VendorProductSizePrice$ / mgStockVerifiedFormatLast verified
Core PeptidesBPC-157, 10mg vial10 mg$97.00$9.70/mgIn stockNo test on fileVial
Core PeptidesBPC-157, 5mg vial5 mg$52.00$10.40/mgIn stockNo test on fileVial
Pure RawzBPC-157 - Peptide, 10mg10mg$119.34$11.93/mgIn stockVerifiedVial
Pure RawzBPC-157, nasal spray 10mg10mg$122.34$12.23/mgIn stockVerifiedNasal
Pure RawzBPC-157 - Peptide, 5mg5mg$71.00$14.20/mgIn stockVerifiedVial

View full BPC-157 comparison →

Latest research

Auto-updated as new studies are published.

Stable Gastric Pentadecapeptide BPC 157 and Wound Healing.

2021Frontiers in pharmacologyReview

This is a review article published in Frontiers in Pharmacology (2021) that focuses specifically on BPC-157 as the primary subject, examining its role in wound healing across multiple tissue types. The review covers preclinical rat model studies on skin wounds (incisional, excisional, burns, diabetic ulcers), fistula healing, and vascular mechanisms, noting BPC-157's effects on gene expression, hemostasis, and vessel function. The authors reference prior ulcerative colitis and multiple sclerosis clinical trials and report no observed toxicity (LD1 not achieved), though the wound healing evidence discussed is largely from animal models.

Source →

BPC 157 Rescued NSAID-cytotoxicity Via Stabilizing Intestinal Permeability and Enhancing Cytoprotection.

2020Current pharmaceutical designData pending

This is a review article examining BPC-157 as a potential protective agent against NSAID-induced gastrointestinal cytotoxicity and leaky gut syndrome. The authors discuss BPC-157's proposed mechanisms including stabilization of intestinal permeability, cytoprotection/adaptive cytoprotection, and endothelial protection across multiple tissues (stomach, liver, pancreas, heart, brain, skin). The review synthesizes preclinical evidence on BPC-157's effects against various GI insults including NSAIDs, alcohol, bile acids, and stress — no human clinical data are presented.

Source →

Gastric pentadecapeptide body protection compound BPC 157 and its role in accelerating musculoskeletal soft tissue healing.

2019Cell and tissue researchReview

This is a review article that critically examines the published literature on BPC-157 as a candidate therapy for musculoskeletal soft tissue healing, with a focus on tendon, ligament, and skeletal muscle repair. The authors note that all studies reviewed to date have shown consistently positive healing effects in small rodent models, but that efficacy in humans has not yet been confirmed. The review also highlights that research has been conducted by only a small number of groups over two decades and calls for further investigation into precise healing mechanisms before clinical translation can be considered.

Source →

BPC 157 and Standard Angiogenic Growth Factors. Gastrointestinal Tract Healing, Lessons from Tendon, Ligament, Muscle and Bone Healing.

2018Current pharmaceutical designReview

This is a review article examining BPC-157 as a primary subject, comparing it to standard angiogenic growth factors (EGF, FGF, VEGF) in the context of gastrointestinal and musculoskeletal tissue healing. The review synthesizes preclinical evidence — including in vivo and in vitro models — showing BPC-157 was consistently effective across multiple injury models (esophagus, stomach, duodenum, lower GI tract, tendon, ligament, muscle, and bone) via intraperitoneal, oral, and local administration routes. The authors argue that BPC-157 uniquely demonstrates a pharmacological angiogenic role that other growth factors have not consistently shown across both gastrointestinal and extragastrointestinal healing contexts.

Source →

The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration.

2011Journal of applied physiology (Bethesda, Md. : 1985)Data pending

This in vitro and ex vivo study directly investigates BPC-157's mechanisms in tendon healing using rat Achilles tendon fibroblasts and tendon explant cultures. Key findings include that BPC-157 accelerated tendon explant outgrowth, enhanced fibroblast survival under oxidative stress (H₂O₂), and dose-dependently increased cell migration and spreading — effects linked to activation of the FAK-paxillin signaling pathway as measured by Western blot. Cell proliferation (MTT assay) was not directly affected, suggesting BPC-157's tendon-healing effects in this model operate through survival and migratory mechanisms rather than proliferation.

Source →

References

  1. [1]Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review. Vasireddi N, Hahamyan H, Salata MJ, Karns M, Calcei JG, Voos JE, Apostolakos JM. HSS Journal, 2025. Review. PubMed →
  2. [2]Regeneration or Risk? A Narrative Review of BPC-157 for Musculoskeletal Healing. McGuire FP, Martinez R, Lenz A, Skinner L, Cushman DM. Current Reviews in Musculoskeletal Medicine, 2025. Review. PubMed →
  3. [3]Intra-Articular Injection of BPC 157 for Multiple Types of Knee Pain. Lee E, Padgett B. Alternative Therapies in Health and Medicine, 2021. PubMed →
  4. [4]Pentadecapeptide BPC 157 and the central nervous system. Vukojevic J, Milavic M, Perovic D, Ilic S, Zemba Cilic A, Duran N, Strbe S, Zoricic Z, Filipcic I, Brecic P, Seiverth S, Sikiric P. Neural Regeneration Research, 2022. PubMed →
  5. [5]Multifunctionality and Possible Medical Application of the BPC 157 Peptide—Literature and Patent Review. Jozwiak M, Bauer M, Kamysz W, Kleczkowska P. Pharmaceuticals, 2025. Review. PubMed →
Compare BPC-157 prices →